Karyopharm Therapeutics
KPTI
147 hedge funds and large institutions have $364M invested in Karyopharm Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 20 closing their positions.
71% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $2.07M
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
20% more capital invested
Capital invested by funds: $303M → $364M (+$61.4M)
0.06% less ownership
Funds ownership: 5.63% → 5.57% (-0.06%)
1% less funds holding
Funds holding: 149 → 147 (-2)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$7.61M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$7.54M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.98M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.31M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.73M |
| 2 |
Morgan Stanley
New York
|
-$6.51M |
| 3 |
Walleye Capital
New York
|
-$5.34M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$4.96M |
| 5 |
Two Sigma Investments
New York
|
-$3.96M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Allianz Asset Management
Munich,
Germany
| – | -$808K | -11,948 | Closed |
|
|
HF
152
HRT Financial
New York
| – | -$221K | -3,269 | Closed |
|
153
Arrowstreet Capital
Boston,
Massachusetts
| – | -$202K | -2,984 | Closed |
|
|
DCM
154
Dupont Capital Management
Wilmington,
Delaware
| – | -$164K | -2,430 | Closed |
|
|
PHK
155
Point72 Hong Kong
Hong Kong
| – | -$131K | -1,941 | Closed |
|
|
VF
156
Virtu Financial
New York
| – | -$59K | -876 | Closed |
|
|
JF
157
Jump Financial
Chicago,
Illinois
| – | -$54K | -809 | Closed |
|
|
QT
158
Quantbot Technologies
New York
| – | -$54K | -804 | Closed |
|
|
PP
159
PDT Partners
New York
| – | -$46K | -682 | Closed |
|
160
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$22K | -329 | Closed |
|
|
PI
161
PEAK6 Investments
Chicago,
Illinois
| – | -$8.15K | -303 | Closed |
|
162
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$5K | -67 | Closed |
|
163
Rockefeller Capital Management
New York
| – | -$4K | -60 | Closed |
|
|
LC
164
Lindbrook Capital
Calabasas,
California
| – | -$971 | -13 | -81% |
|
KPTI Hedge Fund Activity: Q3 2022 in Review
147 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2022, worth a combined $364M — up 20% from $303M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KPTI and 18 opened new positions — a net loss of 2 holders — while 42 trimmed existing stakes and 62 added.
The largest buyer was Ally Bridge Group, opening a new position worth an estimated $7.61M. The largest seller was State Street, cutting an estimated $6.73M.
- 147 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2022, down from 149 in Q2 2022.
- Funds reported $364M of Karyopharm Therapeutics stock for Q3 2022, up 20% quarter-over-quarter.
- 18 funds opened new Karyopharm Therapeutics positions in Q3 2022 and 20 closed out, a net change of -2 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2022 was Ally Bridge Group, an estimated $7.61M added.
- The largest Karyopharm Therapeutics seller in Q3 2022 was State Street, an estimated $6.73M sold.
Based on aggregated 13F filings for Q3 2022.